title: Ponatinib-induced neutrophilic panniculitis.
abstract: Ponatinib is a bcr-abl tyrosine-kinase inhibitor (TKI) used to treat resistant and refractory chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia that express bcr-abl. Neutrophilic panniculitis has been described in rare cases of patients on other TKIs in the same class as ponatinib. We present the first case of neutrophilic panniculitis following treatment with ponatinib and summarize the other cases of panniculitis caused by TKIs.
authors.affiliation: School of Medicine, Washington University in St. Louis, Saint Louis, MO, USA.
authors.forename: May
authors.initials: M
authors.lastname: Zhang
authors.forename: Khaled M
authors.initials: KM
authors.lastname: Hassan
authors.forename: Amy
authors.initials: A
authors.lastname: Musiek
authors.forename: Ilana S
authors.initials: IS
authors.lastname: Rosman
mesh_terms: D005260:Female; D016044:Fusion Proteins, bcr-abl / Q000037:antagonists & inhibitors*; D006801:Humans; D007093:Imidazoles / Q000008:administration & dosage / Q000009:adverse effects*; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000473:pathology; D008875:Middle Aged; D009504:Neutrophils / Q000473:pathology; D015434:Panniculitis / Q000139:chemically induced* / Q000473:pathology*; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage / Q000009:adverse effects*; D011724:Pyridazines / Q000008:administration & dosage / Q000009:adverse effects*
chemical_list: D007093:Imidazoles; D047428:Protein Kinase Inhibitors; D011724:Pyridazines; C545373:ponatinib; D016044:Fusion Proteins, bcr-abl
keywords: chronic myeloid leukemia; drug reaction; panniculitis; ponatinib